NCT02581137View on ClinicalTrials.gov

Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 10, 2016

Primary Completion Date

October 12, 2017

Study Completion Date

December 20, 2025

Conditions
ErythroplakiaHyperplasiaOral Cavity CarcinomaOral Leukoplakia
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Metformin Hydrochloride

Given PO

Trial Locations (4)

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

92103

UC San Diego Medical Center - Hillcrest, San Diego

V5Z 1L3

BC Cancer Research Centre, Vancouver

V6T 2B5

University of British Columbia Hospital, Vancouver

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH